Tag: MONOGRAPH

  • Toloxatone

    Reversible MAO-A inhibitor

    A 5-(hydroxymethyl)oxazolidinone RIMA approved in France in 1984; an early-generation reversible inhibitor of MAO-A.

    Abstract

    Toloxatone (5-(hydroxymethyl)-3-(3-methylphenyl)oxazolidin-2-one; CAS 29218-27-7; molecular formula C11H13NO3; molecular weight 207.23) is an oxazolidinone RIMA developed at Delalande in France and approved there in 1984 under the trade name Humoryl. The compound is a reversible competitive MAO-A inhibitor with a clinical profile broadly comparable to moclobemide; selectivity for MAO-A over MAO-B is approximately 50-fold at therapeutic concentrations. Plasma half-life is approximately 2 hours; hepatic metabolism is the primary clearance pathway. Tyramine restriction is not required at clinical doses. Clinical efficacy in major depressive disorder was demonstrated in French trials but the drug never received approval outside France and clinical use has substantially declined. Used historically and as a reference oxazolidinone RIMA in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Buspirone

    5-HT1A partial agonist anxiolytic

    An azapirone 5-HT1A partial agonist; a non-benzodiazepine anxiolytic without dependence or sedation.

    Abstract

    Buspirone (8-[4-(4-pyrimidin-2-yl-1-piperazinyl)butyl]-8-azaspiro[4.5]decane-7,9-dione; CAS 36505-84-7; molecular formula C21H31N5O2; molecular weight 385.50) is an azapirone 5-HT1A partial agonist developed at Bristol-Myers Squibb and approved by the FDA in 1986 under the trade name BuSpar. The compound is the first clinically approved non-benzodiazepine anxiolytic, distinguished by mechanism (5-HT1A partial agonism rather than GABA-A potentiation), tolerance/dependence profile (none), and absence of sedation. 5-HT1A affinity is approximately 21 nM (intrinsic activity approximately 35 percent); secondary D2 antagonism (Ki approximately 100 nM) is of unclear clinical significance. The active metabolite 1-(2-pyrimidinyl)piperazine (1-PP) is an alpha-2 adrenergic antagonist contributing to noradrenergic effects. Onset of anxiolytic effect is delayed (2 to 4 weeks), reflecting the time course of 5-HT1A autoreceptor desensitization. Plasma half-life is 2 to 3 hours; metabolism is extensive via CYP3A4 with significant first-pass effect (oral bioavailability approximately 4 percent). Approved for generalized anxiety disorder. Used as the canonical 5-HT1A partial agonist in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Exemestane

    Steroidal (suicide) aromatase inhibitor

    A steroidal mechanism-based aromatase inhibitor; irreversibly inactivates aromatase by covalent suicide adduction.

    Abstract

    Exemestane (6-methylenandrosta-1,4-diene-3,17-dione; CAS 107868-30-4; molecular formula C20H24O2; molecular weight 296.40) is a steroidal third-generation aromatase inhibitor developed at Pharmacia (now Pfizer) and approved by the FDA in 1999 under the trade name Aromasin. Distinct from anastrozole and letrozole by mechanism: exemestane is a substrate analog of androstenedione that aromatase begins to process but cannot release, producing irreversible covalent inactivation of the enzyme. Recovery of aromatase activity requires de novo enzyme synthesis. The steroidal scaffold confers weak intrinsic androgenic activity and unique side effect profile (less estrogen-deprivation symptoms in some patients). Plasma half-life is approximately 24 hours; metabolism is hepatic via CYP3A4. Approved for adjuvant and metastatic ER-positive postmenopausal breast cancer. Used as the canonical steroidal suicide aromatase inhibitor in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cagrilintide

    Long-acting amylin analog

    A long-acting amylin analog with attached fatty acid for albumin binding; under development as an obesity treatment in combination with semaglutide.

    Abstract

    Cagrilintide (CAS 1415456-37-9; modified amylin analog with C18 fatty acid attached at lysine for albumin binding; molecular weight approximately 4870 Da) is a long-acting amylin receptor agonist developed by Novo Nordisk for obesity. The compound is structurally derived from pramlintide with addition of a C18 fatty acid linker for albumin binding (the same long-acting strategy as semaglutide), extending plasma half-life from less than 1 hour for amylin to approximately 7 days for cagrilintide. Phase 1 and 2 trials in obesity demonstrated dose-dependent weight loss; in combination with semaglutide (the CagriSema combination), phase 2 trials showed up to 17 percent body weight loss at 32 weeks, approaching the magnitude of bariatric surgery. Phase 3 trials (REDEFINE program) are ongoing. Plasma half-life supports once-weekly subcutaneous dosing. Used as the prototype long-acting amylin agonist in metabolic research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cabergoline

    Long-acting ergoline D2 dopamine agonist

    A long-acting ergoline D2 dopamine receptor agonist; first-line for prolactinoma and used off-label for Parkinson disease maintenance.

    Abstract

    Cabergoline ((6aR,9R,10aS)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-7-(2-propenyl)-ergoline-8-beta-carboxamide; CAS 81409-90-7; molecular formula C26H37N5O2; molecular weight 451.61) is a long-acting ergoline D2 dopamine receptor agonist developed at Pharmacia and approved by the FDA in 1996 under the trade name Dostinex. The compound has high D2 affinity (Ki approximately 0.6 nM) with minimal activity at non-dopaminergic receptors compared to bromocriptine. Plasma half-life is approximately 60 to 100 hours, the longest of any clinical dopamine agonist, supporting twice-weekly oral dosing. Approved for hyperprolactinemia (prolactinoma, idiopathic hyperprolactinemia). Off-label use in Parkinson disease (less common since the introduction of non-ergot agonists), cocaine dependence, and dopamine-deficiency syndromes. The 5-HT2B partial agonism produces a recognized but rare risk of cardiac valvulopathy at high cumulative doses (Parkinson dose ranges); the lower prolactinoma doses are not associated with this risk. Used as the canonical long-acting ergoline dopamine agonist.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Harmaline

    Beta-carboline reversible MAO-A inhibitor

    A beta-carboline alkaloid from Peganum harmala and Banisteriopsis caapi; a reversible MAO-A inhibitor and component of ayahuasca.

    Abstract

    Harmaline (4,9-dihydro-7-methoxy-1-methyl-3H-pyrido[3,4-b]indole; CAS 304-21-2; molecular formula C13H14N2O; molecular weight 214.27) is a beta-carboline alkaloid isolated from Peganum harmala (Syrian rue) and Banisteriopsis caapi (ayahuasca vine). The compound is a reversible MAO-A inhibitor (Ki approximately 5 microM at human MAO-A) with greater than 100-fold selectivity over MAO-B; this reversible MAO-A inhibition is central to the pharmacology of ayahuasca, where harmaline (and harmine) prevent intestinal breakdown of the DMT in the brew, allowing oral activity. Harmaline itself has serotonergic and tremorgenic effects in animals and mild psychoactive effects in humans. Plasma half-life is approximately 2 to 3 hours. Used as a reference reversible MAO-A inhibitor and as a research probe for beta-carboline pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Erythropoietin (EPO)

    Glycoprotein hormone (erythropoiesis-stimulating)

    The hormone that stimulates red blood cell production; recombinant human EPO is approved for anemia and is widely abused in endurance sports.

    Abstract

    Erythropoietin (EPO; CAS 11096-26-7; 165-amino-acid glycoprotein with three N-linked and one O-linked glycan chains; molecular weight approximately 30 kDa) is the principal regulatory hormone of erythropoiesis, produced by interstitial fibroblasts in the renal cortex in response to hypoxia. Recombinant human EPO (epoetin alfa, Procrit, Epogen) was approved by the FDA in 1989 as one of the first commercial recombinant proteins. Mechanism: binding to the EPO receptor (homodimer) on erythroid progenitor cells (BFU-E, CFU-E) prevents apoptosis and stimulates proliferation and differentiation, increasing red blood cell production over 1 to 2 weeks. Approved indications: anemia of chronic kidney disease, chemotherapy-induced anemia, anemia in zidovudine-treated HIV, anemia of prematurity, surgical blood conservation. The compound is among the most notorious performance-enhancing substances in endurance sport (cycling, distance running, cross-country skiing) owing to the oxygen-delivery advantage of supranormal hematocrit; the WADA prohibited list and modern biological passport monitoring address this. Plasma half-life is approximately 4 to 13 hours subcutaneous; longer-acting analogs (darbepoetin, methoxy polyethylene glycol-epoetin beta) extend dosing intervals. Used as the canonical erythropoiesis-stimulating agent in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Progesterone (Research)

    Endogenous progestogen / PR agonist

    The principal endogenous progestogen; a progesterone receptor agonist with luteal phase, gestational, and neurosteroid functions.

    Abstract

    Progesterone (pregn-4-ene-3,20-dione; CAS 57-83-0; molecular formula C21H30O2; molecular weight 314.46) is the principal endogenous progestogen, biosynthesized from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (during pregnancy) placenta. The compound is a high-affinity progesterone receptor (PR) agonist with secondary effects at the glucocorticoid receptor (mineralocorticoid antagonism contributing to natriuretic effects) and at GABA-A receptors (the pregnanolone metabolite is a positive allosteric modulator producing sedation). Approved indications: menopausal hormone therapy (combined with estrogen for endometrial protection in women with intact uterus), assisted reproductive technology luteal support, secondary amenorrhea, and prevention of preterm birth (intramuscular formulation). Oral micronized progesterone (Prometrium) is highly subject to first-pass metabolism producing the sedating allopregnanolone metabolite; vaginal and transdermal forms produce more direct PR effects with less sedation. Plasma half-life is short (5 to 20 minutes for parent; metabolites variable). Used as the canonical PR agonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tacrine

    Aminoacridine acetylcholinesterase inhibitor

    The first FDA-approved Alzheimer disease therapy (1993), withdrawn for hepatotoxicity but historically important and retained as a research probe.

    Abstract

    Tacrine (Cognex, 1,2,3,4-tetrahydroacridin-9-amine; CAS 321-64-2; molecular formula C13H14N2; molecular weight 198.27) is the first FDA-approved cholinesterase inhibitor for Alzheimer disease, granted approval in 1993 and subsequently withdrawn from the US market in 2013 due to hepatotoxicity (approximately 50 percent of patients developed clinically significant ALT elevation requiring monitoring or discontinuation). The compound is a non-selective reversible AChE and BChE inhibitor based on an aminoacridine scaffold. Mechanism includes additional weak NMDA receptor antagonism and modest sodium channel blockade, distinguishing the pharmacology from the more selective subsequent AChE inhibitors. The historical significance of tacrine is substantial; the compound established cholinesterase inhibition as a viable therapeutic strategy for Alzheimer disease and led to development of the more tolerable second-generation agents. The compound retains research utility as a pharmacological probe and AChE reference compound. Pharmacokinetics: short half-life (3 to 4 hours), four-times-daily dosing required in the marketed formulation. Hepatotoxicity is dose-related and reversible on discontinuation in most cases.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tesamorelin

    Stabilized GHRH analog

    A trans-3-hexenoic acid stabilized GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy.

    Abstract

    Tesamorelin (Egrifta; CAS 901758-09-6; molecular weight 5135.79) is a stabilized analog of human GHRH developed by Theratechnologies (Canada) and approved by the FDA in 2010 for HIV-associated lipodystrophy. The structural modification is the addition of a trans-3-hexenoic acid group at the N-terminus, which substantially extends plasma half-life relative to native GHRH or sermorelin. The compound stimulates physiological GH release with restored visceral adipose tissue reduction in HIV patients on antiretroviral therapy. Pharmacokinetics: plasma half-life approximately 26 minutes (versus 11 to 12 minutes for sermorelin); subcutaneous administration.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.